Home
Live Updates
UniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntingtons Disease -December 19, 2023 at 07:06 am EST : vimarsana.com
UniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease -December 19, 2023 at 07:06 am EST
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural...
Related Keywords
Amsterdam ,
Noord Holland ,
Netherlands ,
United Kingdom ,
Chiara Russo ,
Tom Malone ,
Walid Abi Saab ,
Mariae Cantor ,
Phasei Ii Clinical Program ,
National Hospital For Neurology Neurosurgery ,
Us Securities Exchange Commission ,
Huntington Disease Centre ,
University College London ,
Cure Huntington Disease Initiative ,
Securities Exchange ,
Queen Square Institute Of Neurology ,
European Phase ,
Edward Wild ,
Queen Square Institute ,
National Hospital ,
Cure Huntington ,
Disease Initiative ,
Total Functional Capacity ,
Diagnostic Classification Level ,
Total Motor Score ,
Unified Huntington ,
Disease Rating Scale ,
Functional Capacity ,
Motor Score ,
Volumetric Imaging ,
Light Chain ,
Huntingtin Protein ,
Brain Volume ,
Conference Call ,
Qure Forward Looking Statements ,
Securities Act ,
Securities Exchange Act ,
Exchange Commission ,
Annual Report ,
Quarterly Reports ,
Qure Contacts ,
Markets ,
vimarsana.com © 2020. All Rights Reserved.